ECM
FULC icon

ExodusPoint Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

ExodusPoint Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178K Buy
+23,172
New +$215K ﹤0.01% 1393
2024
Q3 		– Sell
-150,505
Closed -$933K – 1776
2024
Q2 		$933K Buy
150,505
+129,086
+603% +$978K 0.01% 1042
2024
Q1 		$202K Sell
21,419
-30,245
-59% -$270K ﹤0.01% 1353
2023
Q4 		$349K Buy
+51,664
New +$229K ﹤0.01% 1135

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

ExodusPoint Capital Management's FULC Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 23,172 shares worth $178K. The stake represents ﹤0.01% of the portfolio and ranks #1393 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in FULC as recently as Q2 2024.

ExodusPoint Capital Management first reported a position in FULC in Q4 2023 and has held it in 4 quarters since. The position peaked at $933K in Q2 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • ExodusPoint Capital Management held 23,172 shares of Fulcrum Therapeutics worth $178K as of Q1 2026.
  • Fulcrum Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1393 holding.
  • ExodusPoint Capital Management first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • ExodusPoint Capital Management's Fulcrum Therapeutics position peaked at $933K in Q2 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.